Table 1

Frequency distribution of Chromosome Aberrations (CA) in 500 bone marrow cells examined (100 cells from each individuals).



Mitotic Index
 Chromosome Aberration
 Micronucleated Erythrocyte
 Sperm Head Anomaly
Fixation Intervals (hr)
 Drug potency
 Series
 % ± SE
 % of Increased MI
 % of Major CA
 % of Other CA
 % of Total CA ± SE
 % of Prot.
 % of MN in NCE
 % of MN in PCE
 P/N
 % of Total MN in NCE & PCE
 % of Prot.
 % of SHA ± SE
 % of prot.
6
 30
 T1
 1.52 ± 0.20
5.4
 6.2
 11.6 ± 1.60
0.25
 0.99
 0.16
 0.35 ± 0.04
1.72 ± 0.13


C1
 1.34 ± 0.17
 0.18
 5.6
 4.4
 10 ± 1.45
 -1.6
 0.24
 0.78
 0.28
 0.41 ± 0.04
 0.06
 1.62 ± 0.12
 -0.1

200
1.72 ± 0.02
4.6
 6
 10.6 ± 1.44
0.18
 1.26
 0.16
 0.33 ± 0.06
1.74 ± 0.09


C2
 1.66 ± 0.16
 0.06
 4,8
 5.8
 10.6 ± 1.44
 0
 0.26
 0.76
 0.30
 0.37 ± 0.04
 0.04
 1.56 ± 0.23
 -0.18
12
 30
 T1
 1.68 ± 0.11
6.8
 8.4
 15.2 ± 1.08
0.23
 0.71
 0.03
 0.33 ± 0.05
1.86 ± 0.13


C1
 1.38 ± 0.12
 0.3
 8
 8.4
 16.4 ± 1.75
 1.2
 0.4
 0.6
 0.47
 0.47 ± 0.04
 0.14a
 2.04 ± 0.20
 0.18

200
 T2
 1.88 ± 0.11
4.4
 7.2
 11.6 ± 1.03
0.25
 0.77
 0.30
 0.37 ± 0.04
1.80 ± 0.15


C2
 1.44 ± 0.19
 0.44
 6.8
 8.4
 15.2 ± 1.55
 3.6
 0.51
 0.7
 0.44
 0.57 ± 0.06
 0.20a
 1.96 ± 0.25
 0.16
24
 30
 T1
 1.68 ± 0.38
9.4
 13.4
 22.8 ± 1.98
0.46
 1.22
 0.38
 0.67 ± 0.06
4.40 ± 0.30


C1
 1.04 ± 0.21
 0.64a
 15.6
 13.9
 29.4 ± 2.28
 6.6
 0.84
 1.68
 0.28
 1.03 ± 0.07
 0.36b
 4.94 ± 0.29
 0.54

200
 T2
 1.84 ± 0.37
8.2
 7.6
 15.8 ± 1.94
0.59
 1.33
 0.33
 0.73 ± 0.05
4.24 ± 0.30


C2
 1.11 ± 0.17
 0.74
 14.8
 13.4
 28.2 ± 1.47
 12.4c
 0.8
 1.51
 0.30
 0.97 ± 0.10
 0.24
 4.74 ± 0.21
 0.5
48
 30
 T1
 1.86 ± 0.13
8.6
 10.2
 18,80,96
0.84
 1.34
 0.48
 1.01 ± 0.08
5.24 ± 0.38


C1
 1.44 ± 0.17
 0.42
 12.6
 12.4
 25 ± 1.36
 6.2b
 1.25
 1.54
 0.44
 1.34 ± 0.12
 0.33a
 5.62 ± 0.31
 0.38

200
 T2
 2.04 ± 0.13
8.6
 7.8
 16.4 ± 1.09
0.87
 1.5
 0.51
 1.07 ± 0.07
5.08 ± 0.38


C2
 1.42 ± 0.23
 0.62
 12.4
 12
 24.4 ± 0.96
 8c
 1.32
 1.44
 0.48
 1.32 ± 0.11
 0.25
 5.68 ± 0.44
 0.6
72
 30
 T1
 2.28 ± 0.18
7.6
 8.6
 16.2 ± 0.89
0.7
 1.23
 0.45
 0.89 ± 0.09
6.18 ± 0.10


C1
 1.52 ± 0.10
 0.76b
 10
 11
 21 ± 1.45
 4.8a
 1.21
 1.64
 0.62
 1.38 ± 0.04
 0.49c
 7.02 ± 0.20
 0.84b

200
 T2
 2.5 ± 0.20
5.8
 6.6
 12.4 ± 1.81
0.64
 1.24
 0.40
 0.83 ± 0.13
6.16 ± 0.24


C2
 1.86 ± 0.23
 0.64
 9.8
 9.6
 19.4 ± 1.48
 7b
 1.5
 1.16
 0.59
 1.38 ± 0.13
 0.55a
 6.98 ± 0.30
 0.82
96
 30
 T1
 1.98 ± 0.20
6
 9.2
 15.2 ± 0.65
0.44
 1.22
 0.32
 0.63 ± 0.05
3.62 ± 0.54


C1
 1.64 ± 0.16
 0.34
 9.4
 9
 18.4 ± 1.44
 3.2
 1.01
 1.11
 0.51
 1.03 ± 0.08
 0.40b
 4.68 ± 0.60
 1.06

200
 T2
 2.2 ± 0.22
5.
 7
 12 ± 2.44
0.39
 0.95
 0.33
 0.53 ± 0.04
3.80 ± 0.29


C2
 1.48 ± 0.10
 0.72a
 8.2
 8.2
 16.6 ± 1.15
 4.6
 0.91
 0.96
 0.53
 0.93 ± 0.11
 0.40b
 5.12 ± 0.10
 1.32b

a = p < 0.05, b = p < 0.01, c = p < 0.001 (significance levels of t-test) Mitotic Indices (MI) in 5000 cells (1000 cells from each individuals), Micronuclei in normochromatic erythrocytes (NCE) and polychromatic erythrocytes (PCE) in 5000 cells (1000 cells from each individuals) and Sperm head-shape abnormality (SHA) in 5000 sperm (1000 sperm from each individuals) at different fixation intervals in CdCl2 treated mice pre-fed with Cad Sulph-30 (T1) and Cad Sulph-200 (T2) separately and respective alcohol-30 (C1) and alcohol-200 (C2) fed controls.

Datta et al. BMC Complementary and Alternative Medicine 2001 1:9   doi:10.1186/1472-6882-1-9